Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Looks To Expand Beovu’s Use And Move On From Safety Scare

Diabetic Macular Edema (DME) Filing Possible In 2021

Executive Summary

New data for a further indication should help Novartis rebuild momentum for competitor to Eylea, but safety concerns could take years to overcome.

You may also be interested in...



First COVID-19 Trial Success For Roche’s Actemra, But No Sign It Saves Lives

A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.

Moderna Expands Horizons With Vertex and Chiesi Deals

The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth

Two New Biotechs Spin Out From Edinburgh’s Regenerative Medicine Centre

Scotland’s investment in regenerative medicine is paying off with two promising start-ups, one targeting liver disease, the other oncology, launching within days of each other.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel